New therapeutic targets for myocardial infarction

Current Science

Volumn 95, Issue 3, 2008, Pages 332-339

  Goyal, S N ^a   Arora, S ^a   Nandave, M ^a   Ojha, S K ^a   Kumari, S ^b   Arya, D S ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b INDIAN AGRICULTURAL RESEARCH INSTITUTE   (India)

Author keywords

Coronary artery disease; Ischaemia reperfusion; Myocardial infarction; Oxidative stress; Therapeutic targets

Indexed keywords

EID: 49449091642     PISSN: 00113891     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Karmazyn, M., Ischemic and reperfusion injury in the heart: Cellular mechanism and pharmacological intervention. Can. J. Physiol. Pharmacol., 1991, 69, 719-730.
2. Fryer, R. M., Auchampach, J. A. and Gross, G. J., Therapeutic receptor targets of ischaemic preconditioning. Cardiovasc. Res., 2002, 55, 520-525.
3. Vinten-Johansen, J., Zhao, Z. Q., Jiang, R., Zatta, A. J. and Dobson, G. P., Preconditioning and postconditioning: Innate cardioprotection from ischemia-reperfusion injury. J. Appl. Physiol., 2007, 5, 591-598.
4. Yellon, D. M. and Latchman, D. S., Stress protein and myocardial protection. J. Mol. Cell. Cardiol., 1992, 24, 113-124.
5. Liu, L., Zhang, X. J., Jiang, S. R., Ding, Z. N., Ding, G. X., Huang, J. and Cheng, Y. L., Heat shock protein 27 regulates oxidative stress-induced apoptosis in cardiomyocytes: Mechanisms via reactive oxygen species generation and Akt activation. Chin. Med. J., 2007, 120, 2271-2277.
6. Currie, R. W., Karmazgn, M., Kloe, M. and Mailer, K., Heat-shock response is associated with enhanced post-ischaemic ventricular recovery. Circ. Res., 1998, 63, 543-549.
7. Walsh, R. C., Koukoulas, I., Garnham, A., Moseley, P. L., Hargreaves, M. and Febbraio, M. A., Exercise increases serum Hsp72 in humans. Cell Stress Chaperones, 2001, 6, 386-393.
8. Sawa, Y., Bai, H. Z. and Suznki, K., Overexpression of Bcl-2 gene improves the myocardial tolerance to ischaemia-reperfusion by preventing DNA fragmentation. Circulation, 1995, 92, 1-525.
9. Gustafsson, A. B. and Gottlieb, R. A., Mechanisms of apoptosis in the heart. J. Clin. Immunol., 2003, 23, 447-459.
10. Olivetti, G., Cigola, E., Maestri, R., Lagrasta, C. and Quaini, F., The failing heart. Adv. Clin. Pathol., 1997, 1, 137-148.
11. (+) exchanger. Eur. J. Med. Chem., 2003, 38, 547-554.
12. + exchange in ischaemia-reperfusion. Basic Res. Cardiol., 1996, 91, 191-202.
13. + exchanger isoform NHE1 by a novel aminoguanidine derivative T-162559. Eur. J. Pharmacol., 2001, 420, 1-8.
14. + channels in cardiac muscle. Nature, 1983, 305, 147-148.
15. + channels and myocardial preconditioning. Circ. Res., 1999, 84, 973-979.
16. Sullivan, M. E., Thompson, C. S., Dashwood, M. R., Khan, M. A., Jeremy, J. Y., Morgan, R. J. and Mikhailidis, D. P., Nitric oxide and penile erection: Is erectile dysfunction another manifestation of vascular disease? Cardiovasc Res., 1999, 43, 658-665.
17. Berger, J. and Moller, D. E., The mechanisms of action of PPARs. Annu. Rev. Med., 2002, 53, 409-435.
18. Chinetti, G., Fruchart, J. C. and Staels, B., Peroxisome proliferator-activated receptors (PPARs): Nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm. Res., 2000, 49, 497-505.
19. Pieper, A. A., Verma, A., Zhang, J. and Snyder, S. H., Poly(ADP-ribose) polymerase, nitric oxide and cell death. Trends Pharmacol. Sci., 1999, 20, 171-181.
20. Garcia Soriano, F. et al., Diabetic endothelial dysfunction: The role of poly(ADP-ribose) polymerase activation. Nature Med., 2001, 7, 108-113.
21. Thiemermann, C., Bowes, J., Myint, F. P. and Vane, J. R., Inhibition of the activity of poly(ADP ribose) synthetase reduces ischaemia-reperfusion injury in the heart and skeletal muscle. Proc. Natl. Acad. Sci. USA, 1997, 94, 679-683.
22. Cuzzocrea, S., Zingarelli, B., Costantino, G., Szabo, A., Salzman, A. L., Caputi, A. P. and Szabo, C., Beneficial effects of 3-aminobenzamide, an inhibitor of poly(ADP-ribose) synthetase in a rat model of splanchnic artery occlusion and reperfusion. Br. J. Pharmacol., 1997, 121, 1065-1074.
23. Griffin, R. J., Curtin, N. J., Newell, D. R., Golding, B. T., Durkacz, B. W. and Calvert, A. H., The role of inhibitors of poly (ADP-ribose) polymerase as resistance-modifying agents in cancer therapy. Biochimie, 1995, 77, 408-422.
24. Belardinelli, L., Linden, J. and Berne, R. M., The cardiac effects of adenosine. Prog. Cardiovasc. Dis., 1989, 32, 73-97.
25. Norton, E. D., Jackson, E. K., Turner, M. B., Virmani, R. and Forman, M. B., The effects of intravenous infusions of selective adenosine A1-receptor and A2-receptor agonists on myocardial reperfusion injury. Am. Heart J., 1992, 123, 332-338.
26. Xu, Z., Downey, J. M. and Cohen, M. V., Amp 579 reduces contracture and limits infarction in rabbit heart by activating adenosine A2 receptors. J. Cardiovasc. Pharmacol., 2001, 38, 474-481.
27. Zorov, D. B., Juhaszova, M. and Sollott, S. J., Mitochondrial ROS-induced ROS release: An update and review. Biochim. Biophys. Acta, 2006, 1757, 509-517.
28. Jaruga, E., Sokal, A., Chrul, S. and Bartosz, G., Apoptosis-independent alterations in membrane dynamics induced by curcumin. Exp. Cell. Res., 1998, 245, 303-312.
29. Li, T. and Singal, P. K., Adriamycin-induced early changes in myocardial antioxidant enzymes and their modulation by probucol. Circulation, 2000, 102, 2105-2110.
30. Hwang, Y. C. et al., Aldose reductase activation is a key component of myocardial response to ischaemia. FASEB J., 2002, 16, 243-245.
31. Aronow, W. S., Antiplatelet therapy in the treatment of atherothrombotic disease: Considering the evidence. Geriatrics, 2007, 62, 12-24.
32. Braunwald, E. et al., Antiplatelet strategies: Evaluating their current role in the setting of acute coronary syndromes. Clin. Cardiol., 2008, 31, 12-19.
33. Wenaweser, P. and Windecker, S., Acute coronary syndromes: Management and secondary prevention. Herz, 2008, 33, 25-37.
34. Wild, D. M. and Kukin, M., Beta-blockers to prevent symptomatic heart failure in patients with stage A and B heart failure. Curr. Heart Fail. Rep., 2007, 4, 99-102.
35. Doughty, R. N. and White, H. D., Carvedilol: Use in chronic heart failure. Expert Rev. Cardiovasc. Ther., 2007, 5, 21-31.
36. Thomas, F., Cher, Lu and Barton, M., Endothelins and endothelin receptor antagonists: Therapeutic considerations for a novel class of cardiovascular drugs. Circulation, 2000, 102, 2434-2440.
37. Caliezi, C., Wuillemin, W. A., Zeerleder, S., Redondo, M., Eisele, B. and Hack, C. E., C1-Esterase inhibitor: An anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol. Rev., 2000, 52, 91-112.
38. Moss, N. C., Stansfield, W. E., Willis, M. S., Tang, R. and Selzman, C. H., Inhibitory kappa B kinase beta (IKK{beta}) inhibition attenuates myocardial injury and dysfunction following acute ischemia-reperfusion injury. Am. J. Physiol. Heart Circ. Physiol., 2007, 3, 215-223.
39. Ferraccioli, G. and Gremese, E., Thrombogenicity of TNF-alpha in rheumatoid arthritis defined through biological probes: TNF alpha blockers. Autoimmun. Rev., 2004, 3, 261-266.
40. Lazaros, A. N., Mankad, S., Sokos, G. S., Miske, G., Shah, A. and Richard, P., Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation, 2004, 109, 962-965.
41. Kaplan, R. C., Strickler, H. D., Rohan, T. E., Muzumdar, R. and Brown, D. L., Insulin-like growth factors and coronary heart disease. Cardiol. Rev., 2005, 13, 35-39.
42. Lange, S. A., Wolf, B., Schober, K., Wunderlich, C., Marquetant, R., Weinbrenner, C. and Strasser, R. H., Chronic angiotensin II receptor blockade induces cardioprotection during ischaemia by increased PKC-epsilon expression in the mouse heart. J. Cardiovasc. Pharmacol., 2007, 49, 46-55.